“Performance of elecsys anti- Sars Cov-2 (ROCHE) and vidas anti Sars Cov-2 (BIOMÉRIEUX) for Sars Cov-2 Nucleocapsid and spike protein antibody detection"
Abstract: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the novel viral pathogen that causes coronavirus disease 2019 (COVID-19) in humans, has spread worldwide since its identification in late 2019. The pandemic produced an accelerated development of new serological techni...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2021
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/35069 |
| Aporte de: |
| id |
I10-R327-article-35069 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| format |
Artículo revista |
| topic |
performance diagnosis antibody detection anticuerpos Diagnóstico desempeño |
| spellingShingle |
performance diagnosis antibody detection anticuerpos Diagnóstico desempeño Alfaro , J Riberi , MI Hernandez Toledo , MG Cid , MP Tenaglia , MM Konigheim , BS Aguilar , JJ Blanco , S “Performance of elecsys anti- Sars Cov-2 (ROCHE) and vidas anti Sars Cov-2 (BIOMÉRIEUX) for Sars Cov-2 Nucleocapsid and spike protein antibody detection" |
| topic_facet |
performance diagnosis antibody detection anticuerpos Diagnóstico desempeño |
| author |
Alfaro , J Riberi , MI Hernandez Toledo , MG Cid , MP Tenaglia , MM Konigheim , BS Aguilar , JJ Blanco , S |
| author_facet |
Alfaro , J Riberi , MI Hernandez Toledo , MG Cid , MP Tenaglia , MM Konigheim , BS Aguilar , JJ Blanco , S |
| author_sort |
Alfaro , J |
| title |
“Performance of elecsys anti- Sars Cov-2 (ROCHE) and vidas anti Sars Cov-2 (BIOMÉRIEUX) for Sars Cov-2 Nucleocapsid and spike protein antibody detection" |
| title_short |
“Performance of elecsys anti- Sars Cov-2 (ROCHE) and vidas anti Sars Cov-2 (BIOMÉRIEUX) for Sars Cov-2 Nucleocapsid and spike protein antibody detection" |
| title_full |
“Performance of elecsys anti- Sars Cov-2 (ROCHE) and vidas anti Sars Cov-2 (BIOMÉRIEUX) for Sars Cov-2 Nucleocapsid and spike protein antibody detection" |
| title_fullStr |
“Performance of elecsys anti- Sars Cov-2 (ROCHE) and vidas anti Sars Cov-2 (BIOMÉRIEUX) for Sars Cov-2 Nucleocapsid and spike protein antibody detection" |
| title_full_unstemmed |
“Performance of elecsys anti- Sars Cov-2 (ROCHE) and vidas anti Sars Cov-2 (BIOMÉRIEUX) for Sars Cov-2 Nucleocapsid and spike protein antibody detection" |
| title_sort |
“performance of elecsys anti- sars cov-2 (roche) and vidas anti sars cov-2 (biomérieux) for sars cov-2 nucleocapsid and spike protein antibody detection" |
| description |
Abstract:
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the novel viral pathogen that causes coronavirus disease 2019 (COVID-19) in humans, has spread worldwide since its identification in late 2019. The pandemic produced an accelerated development of new serological techniques for diagnosis.
Herein, we evaluated two commercial assays for serological diagnosis of SARS-CoV-2 infection: Elecsys Anti-SARS CoV-2 (Roche), for nucleocapsid total antibody detection and VIDAS Anti- SARS CoV-2 (bioMérieux), for spike protein IgG antibody detection.
The Elecsys Anti-SARS CoV-2 assay was performed on a Cobas e411 analyzer (Roche Diagnostics) and conducted according to the manufacturer’s instructions. Results are expressed as (cut-off index, negative COI <1 or positive COI ≥1) for anti-SARS CoV-2 total antibodies. The VIDAS SARS-CoV-2 IgG assay was performed on a VIDAS analyzer (bioMérieux) and conducted according to the manufacturer’s instructions. Results are interpreted as negative (index <1) or positive (index ≥1). Sensitivity was assessed using a panel of 92 plasma samples from recovered COVID-19 patients who were positive for RT-PCR and positive for neutralizing antibodies by PRNT and/or positive for IgG antibodies by indirect immunofluorescence assay (IFA). Specificity was determined studying 71 plasma samples collected during year 2018, prior to the COVID-19 pandemic. Categorical variables were compared using Fisher’s exact test (CI 95%). Additionally, concordance between the two commercial assays was analyzed using Cohen's kappa coefficient (κ).
Sensitivity: 97.83% and 98.91% for Roche and bioMérieux assays, respectively, specificity: 98.59% (Roche) and 97.18% (bioMérieux), positive predictive value (PPV): 98.90% (Roche) and 97.85% (bioMérieux), and negative predictive value: (NPV) 97.22% (Roche) and 98.57% (bioMérieux). Additionally, Cohen's kappa coefficient demonstrated high concordance (k=0.950) between Elecsys Anti-SARS CoV-2 and VIDAS Anti-SARS CoV-2.
In conclusion, these results evidenced a very good performance for both, the nucleocapsid antibody assay (Elecsys Anti-SARS CoV-2; Roche) and the spike protein antibody assay (VIDAS Anti-SARS CoV-2; bioMérieux), being both platforms equally adequate for indirect diagnosis of SARS-CoV-2 infection through total antibodies and IgG antibody detection, respectively. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2021 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/35069 |
| work_keys_str_mv |
AT alfaroj performanceofelecsysantisarscov2rocheandvidasantisarscov2biomerieuxforsarscov2nucleocapsidandspikeproteinantibodydetection AT riberimi performanceofelecsysantisarscov2rocheandvidasantisarscov2biomerieuxforsarscov2nucleocapsidandspikeproteinantibodydetection AT hernandeztoledomg performanceofelecsysantisarscov2rocheandvidasantisarscov2biomerieuxforsarscov2nucleocapsidandspikeproteinantibodydetection AT cidmp performanceofelecsysantisarscov2rocheandvidasantisarscov2biomerieuxforsarscov2nucleocapsidandspikeproteinantibodydetection AT tenagliamm performanceofelecsysantisarscov2rocheandvidasantisarscov2biomerieuxforsarscov2nucleocapsidandspikeproteinantibodydetection AT konigheimbs performanceofelecsysantisarscov2rocheandvidasantisarscov2biomerieuxforsarscov2nucleocapsidandspikeproteinantibodydetection AT aguilarjj performanceofelecsysantisarscov2rocheandvidasantisarscov2biomerieuxforsarscov2nucleocapsidandspikeproteinantibodydetection AT blancos performanceofelecsysantisarscov2rocheandvidasantisarscov2biomerieuxforsarscov2nucleocapsidandspikeproteinantibodydetection AT alfaroj desempenoclinicodeelecsysantisarscov2rocheyvidasantisarscov2biomerieuxparaladetecciondeanticuerposdenucleocapsideyproteinadeespiculadelsarscov2 AT riberimi desempenoclinicodeelecsysantisarscov2rocheyvidasantisarscov2biomerieuxparaladetecciondeanticuerposdenucleocapsideyproteinadeespiculadelsarscov2 AT hernandeztoledomg desempenoclinicodeelecsysantisarscov2rocheyvidasantisarscov2biomerieuxparaladetecciondeanticuerposdenucleocapsideyproteinadeespiculadelsarscov2 AT cidmp desempenoclinicodeelecsysantisarscov2rocheyvidasantisarscov2biomerieuxparaladetecciondeanticuerposdenucleocapsideyproteinadeespiculadelsarscov2 AT tenagliamm desempenoclinicodeelecsysantisarscov2rocheyvidasantisarscov2biomerieuxparaladetecciondeanticuerposdenucleocapsideyproteinadeespiculadelsarscov2 AT konigheimbs desempenoclinicodeelecsysantisarscov2rocheyvidasantisarscov2biomerieuxparaladetecciondeanticuerposdenucleocapsideyproteinadeespiculadelsarscov2 AT aguilarjj desempenoclinicodeelecsysantisarscov2rocheyvidasantisarscov2biomerieuxparaladetecciondeanticuerposdenucleocapsideyproteinadeespiculadelsarscov2 AT blancos desempenoclinicodeelecsysantisarscov2rocheyvidasantisarscov2biomerieuxparaladetecciondeanticuerposdenucleocapsideyproteinadeespiculadelsarscov2 |
| first_indexed |
2024-09-03T21:03:06Z |
| last_indexed |
2024-09-03T21:03:06Z |
| _version_ |
1809210290359762944 |
| spelling |
I10-R327-article-350692024-04-15T16:19:09Z “Performance of elecsys anti- Sars Cov-2 (ROCHE) and vidas anti Sars Cov-2 (BIOMÉRIEUX) for Sars Cov-2 Nucleocapsid and spike protein antibody detection" “Desempeño clínico de Elecsys anti-SARS CoV-2 (Roche) y VIDAS anti-SARS CoV-2 (bioMérieux) para la detección de anticuerpos de nucleocápside y proteína de espícula del SARS-CoV-2 " Alfaro , J Riberi , MI Hernandez Toledo , MG Cid , MP Tenaglia , MM Konigheim , BS Aguilar , JJ Blanco , S performance diagnosis antibody detection anticuerpos Diagnóstico desempeño Abstract: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the novel viral pathogen that causes coronavirus disease 2019 (COVID-19) in humans, has spread worldwide since its identification in late 2019. The pandemic produced an accelerated development of new serological techniques for diagnosis. Herein, we evaluated two commercial assays for serological diagnosis of SARS-CoV-2 infection: Elecsys Anti-SARS CoV-2 (Roche), for nucleocapsid total antibody detection and VIDAS Anti- SARS CoV-2 (bioMérieux), for spike protein IgG antibody detection. The Elecsys Anti-SARS CoV-2 assay was performed on a Cobas e411 analyzer (Roche Diagnostics) and conducted according to the manufacturer’s instructions. Results are expressed as (cut-off index, negative COI <1 or positive COI ≥1) for anti-SARS CoV-2 total antibodies. The VIDAS SARS-CoV-2 IgG assay was performed on a VIDAS analyzer (bioMérieux) and conducted according to the manufacturer’s instructions. Results are interpreted as negative (index <1) or positive (index ≥1). Sensitivity was assessed using a panel of 92 plasma samples from recovered COVID-19 patients who were positive for RT-PCR and positive for neutralizing antibodies by PRNT and/or positive for IgG antibodies by indirect immunofluorescence assay (IFA). Specificity was determined studying 71 plasma samples collected during year 2018, prior to the COVID-19 pandemic. Categorical variables were compared using Fisher’s exact test (CI 95%). Additionally, concordance between the two commercial assays was analyzed using Cohen's kappa coefficient (κ). Sensitivity: 97.83% and 98.91% for Roche and bioMérieux assays, respectively, specificity: 98.59% (Roche) and 97.18% (bioMérieux), positive predictive value (PPV): 98.90% (Roche) and 97.85% (bioMérieux), and negative predictive value: (NPV) 97.22% (Roche) and 98.57% (bioMérieux). Additionally, Cohen's kappa coefficient demonstrated high concordance (k=0.950) between Elecsys Anti-SARS CoV-2 and VIDAS Anti-SARS CoV-2. In conclusion, these results evidenced a very good performance for both, the nucleocapsid antibody assay (Elecsys Anti-SARS CoV-2; Roche) and the spike protein antibody assay (VIDAS Anti-SARS CoV-2; bioMérieux), being both platforms equally adequate for indirect diagnosis of SARS-CoV-2 infection through total antibodies and IgG antibody detection, respectively. Resumen: El nuevo coronavirus SARS-CoV-2 fue identificado en el 2019, causa el síndrome respiratorio agudo (Covid-19) provocando miles de infecciones a nivel mundial. La pandemia produjo un desarrollo acelerado de nuevas técnicas serológicas para el diagnóstico. Evaluar el desempeño clínico de dos ensayos comerciales automatizados usados para el diagnóstico serológico de la infección por SARS-CoV-2, Elecsys Anti-SARS CoV-2 (Roche) para detectar anticuerpos totales contra la nucleocápside y VIDAS Anti-SARS CoV-2 (bioMérieux) para anticuerpos contra la proteína de espícula tipo IgG. Se realizó la detección de anticuerpos totales en muestras de plasma con Elecsys Anti-Sars-Cov-2 en Cobas E411(Roche). El valor de corte para resultados negativos fue coi < 1 y para valores positivos se consideró coi ≥1. El análisis de las muestras para determinar anticuerpos contra la espícula tipo IgG se realizó con el reactivo 9-COG en Vidas (bioMerieux). El índice de corte para valores negativos fue vt < 1 y para valores positivos vt ≥ 1. La sensibilidad se evaluó en un panel de 92 muestras de personas con Covid-19 recuperados que fueron positivos para RT-PCR, para anticuerpos neutralizantes por PRNT y / o para anticuerpos IgG por ensayo de inmunofluorescencia indirecta (IFA). La especificidad se determinó mediante 71 muestras recolectadas durante el año 2018. Los resultados del desempeño fueron analizados con test de Fisher (IC 95%) y se usó el índice de kappa de Cohen para determinar la concordancia entre ambos métodos. La sensibilidad fue del 97,83% y del 98,91% para los ensayos de Roche y bioMerieux, respectivamente. Además, encontramos especificidad 98,59% (Roche) y 97,18% (bioMerieux), valor predictivo positivo (VPP) 98,90% (Roche) 97,85% (bioMerieux) y valor predictivo negativo (VPN) 97,22% (Roche) y 98,57% (bioMerieux). Se analizó el coeficiente kappa de Cohen, mostrando una alta concordancia (k = 0,950) entre Roche y bioMerieux. Los resultados evidenciaron un muy buen desempeño clínico, para el ensayo de anticuerpos de nucleocápside (Roche) y para el ensayo de anticuerpos de proteínas de espícula (bioMerieux), siendo ambas plataformas igualmente adecuadas para el diagnóstico indirecto de la infección por SARS-CoV-2 mediante la detección de anticuerpos totales y anticuerpos IgG, respectivamente Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2021-10-12 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion texto texto texto https://revistas.unc.edu.ar/index.php/med/article/view/35069 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 78 No. Suplemento (2021): Suplemento JIC XXII Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 78 Núm. Suplemento (2021): Suplemento JIC XXII Revista da Faculdade de Ciências Médicas de Córdoba; v. 78 n. Suplemento (2021): Suplemento JIC XXII 1853-0605 0014-6722 http://creativecommons.org/licenses/by-nc/4.0 |